New wet AMD treatment a step closer

March 25, 2009

The CABERNET (CNV Secondary to AMD Treated with Beta RadiatioN Epiretinal Therapy) clinical trial is pivotal to establishing the safety and effectiveness of a beta radiation based focal epimacular brachytherapy device. Its development in bringing a paradigm shift in the way retina specialists treat wet AMD patients moved a step closer as Neovista Inc. secured more than $18 million in its Series D private venture funding round.

The CABERNET (CNV Secondary to AMD Treated with Beta RadiatioN Epiretinal Therapy) clinical trial is pivotal to establishing the safety and effectiveness of a beta radiation based focal epimacular brachytherapy device. Its development in bringing a paradigm shift in the way retina specialists treat wet AMD patients moved a step closer as Neovista Inc. secured more than $18 million in its Series D private venture funding round.

The product is designed to replace the need for frequent anti-VEGF injections, which can be a requirement for an indefinite time period. CNV (choroidal neovascularization) is a result of over-expression of vascular endothelial growth factor, recruitment of inflammatory cells, and fibroblasts. Unlike anti-VEGF agents, radiation is thought to eliminate CNV vessels permanently, rather than simply suppress them. For this reason, the device offers the prospect of a one-off operation. Initial trials suggest the treatment is safe and effective, with results remaining stable over time.

NeoVista intends to bring the technology to Europe in May 2009 and chairman of the NeoVista board, William J. Link, is extremely optimistic: "If the data ultimately proves to support the science, the patient population suffering from this disease will benefit tremendously."

European countries participating in the CABERNET trial include the UK, Austria, Spain, Germany and Switzerland. Ophthalmologists can find out more in the April issue of Ophthalmology Times Europe.